Every 10-Q that BioCardia, Inc. (BCDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCDA filings page.
BioCardia, Inc. reported a smaller net loss while strengthening its balance sheet but continues to face severe funding risk. For the six months ended June 30, 2026, net loss was $3.9 million compared with $4.8 million a year earlier, as research and development expenses declined to $2.1 million from $2.9 million with the CardiAMP Heart Failure Trial winding down. Selling, general and administrative costs stayed roughly flat at $1.8 million.
Cash and cash equivalents increased to $4.1 million from $2.5 million at year-end 2025, driven by $5.3 million in gross proceeds from at-the-market stock sales in the first half of 2026. Stockholders’ equity improved to $2.7 million. Management nonetheless states there is substantial doubt about the company’s ability to continue as a going concern beyond January 2027 without additional capital. Operationally, BioCardia highlights regulatory momentum: Japan’s PMDA feedback supports a CardiAMP submission in ischemic heart failure, and FDA minutes indicate the ongoing CardiAMP Heart Failure II trial may support Premarket Approval. Early CardiAMP chronic myocardial ischemia data and progress on the CardiALLO and Heart3D platforms are also described.
BioCardia, Inc. reported a Q1 2026 net loss of $2.259M, narrowing from $2.712M a year earlier, as research and development and selling, general and administrative expenses both declined. Cash and cash equivalents were $951,000 as of March 31, 2026, with total assets of $1.712M and stockholders’ deficit of $1.066M.
The company states that existing cash is not sufficient to fund planned operations beyond June 2026 and discloses substantial doubt about its ability to continue as a going concern without new financing. BioCardia continues to rely on its at-the-market equity program, selling 184,725 shares for gross proceeds of $225,000 in the quarter, and may sell up to about $5.1M more under this facility.
Clinically, the CardiAMP heart failure program generated subgroup data suggesting fewer heart-death equivalents and improved quality of life, supporting regulatory interactions. Japan’s PMDA indicated CardiAMP evidence is likely sufficient to support market clearance and aligned on a path toward Shonin submission, while the U.S. FDA reaffirmed Premarket Approval as the appropriate pathway and recommended continuing the CardiAMP HF II confirmatory trial. The Helix delivery catheter also advanced via an FDA pre-submission, with regulators outlining potential approval pathways.
BioCardia, Inc. filed an amended Q2 2025 10‑Q solely to add the CEO/CFO certifications omitted from the original filing; no other changes were made.
For the quarter ended June 30, 2025, the company reported a net loss of $2.049 million on operating expenses of $2.051 million. Cash and cash equivalents were $980,000 and stockholders’ equity was a deficit of $(1.886) million. Management states there is “substantial doubt” about continuing as a going concern, noting existing cash is not sufficient beyond October 2025. Shares outstanding were 5,504,802 as of June 30, 2025.
Research and development expense was $1.368 million and selling, general and administrative was $683,000. Subsequent to quarter‑end, the company updated its ATM capacity on July 8, 2025 and sold 296,422 shares for gross proceeds of $769,000 through August 8, 2025. The company also disclosed a Nasdaq notice with an extension to regain equity compliance by September 29, 2025. There were 5,801,224 common shares outstanding as of August 8, 2025.